Arnold J describes SPC system as 'dysfunctional'
Arnold J has handed down a judgment referring yet another SPC question to the CJEU in GlaxoSmithKline Biologicals SA v Comptroller  EWHC 619 (Pat). The referral relates to GSK’s applications for SPCs on an adjuvant (AS03) that it has developed alone, and in combination with an influenza virus antigen.
Previous case law of the CJEU (Pharmacia, MIT and Yissum) suggests that adjuvants are not “active ingredients” and so do not come within the definition of “product” in Article 1(b) of Council Regulation 469/2009/EC (the SPC Regulation) and cannot be the subject of a certificate. On the other hand, in order to give effect to the overriding objective of the SPC Regulation - that is to encourage research - Neurim interpreted “product” more broadly by including a purpose within the definition…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
Why register to The Lawyer
More relevant to you
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
For the tax year from 6 April 2014, the standard lifetime allowance has reduced from £1.5m to £1.25m.
One of the areas highlighted last year by the Regulator was the regulation of workplace DC pension schemes.
Analysis from The Lawyer
As the equity capital markets rocketed back into favour and global M&A saw at least a partial return to form, there have been some rich pickings for The Lawyer’s Corporate Team of the Year award shortlisted firms in 2014.
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world